Evaluation of the safety and efficacy of m-beam and m-beac regimen for autologous hematopoietic stem-cell transplantation pretreatment due to the shortage supply of melphalan (the second report)

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: MIYAGAWA, Keiko (Kameda Medical Center, Kamogawa, Chiba, Japan)
  • Co-author(s): Keiko Miyagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Yusuke Nakagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Tatsuya Isezaki: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Koji Masuda: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Osamu Yasumuro: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Kosei Matsue: Department of Hematology, Kameda Medical Center, Chiba, Japan
    Ryokan Funakoshi: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  • Abstract:

    Methods

    We retrospectively reviewed the medical records of pre-ASCT patients treated with M-BEAM for non-Hodgkin’s lymphoma between April and November 2014 and those treated with M-BEAC between December 2015 and January 2016. Our goals were to compare patients’ characteristics, days to engraftment, adverse reactions, one-year survival, and..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login